Skip to content

Clinical Evaluation of Fortilink® TETRAfuse® Interbody Fusion Device in Subjects With Degenerative Disc Disease

Clinical Evaluation of Fortilink® TETRAfuse® Interbody Fusion Device in Subjects With Degenerative Disc Disease (FORTE)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03761563
Acronym
FORTE
Enrollment
15
Registered
2018-12-03
Start date
2019-02-13
Completion date
2023-12-30
Last updated
2024-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Degenerative Disc Disease

Brief summary

This is a prospective, multi-center, non-randomized post-market evaluation designed to collect and evaluate data on the safety and performance of the Fortilink IBF System with TETRAfuse 3D Technology.

Detailed description

This is a prospective, multi-center, non-randomized post-market evaluation designed to collect and evaluate data on the safety and performance of the Fortilink IBF System with TETRAfuse 3D Technology. There will be 3 arms in the study, one for each configuration of the Fortilink IBF system (Fortilink-C, Fortilink-TS and Fortilink-L). Up to 50 subjects will be enrolled in each study arm for a total of up to 150 subjects at up to 20 sites in the United States (US) and European Union (EU).

Interventions

Cervical and lumbar fusion

Sponsors

Xtant Medical
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* The subject is skeletally mature and at least 18 years of age. * The subject has degenerative disc disease (DDD) of the cervical spine with accompanying radicular symptom at one or two contiguous levels (Fortilink-C), or the subject has DDD and ≤ Grade 1 spondylolisthesis of the lumbar spine at one or two contiguous levels (Fortilink-TS and Fortilink-L). * Subject plans to undergo one of the following procedures: An anterior cervical interbody fusion at one to two continuous levels from C2-C3 to C7-T1 using autogenous or allogenic bone graft and supplemental fixation cleared and indicated for use at the proposed treatment level(s) (Fortilink-C), or An interbody fusion in the lumbar spine at one to two continuous levels from L1-L2 to L5-S1 using autogenous or allogenic bone graft and supplemental fixation cleared and indicated for use at the proposed treatment level(s) (Fortilink-TS and Fortilink-L). * The subject has undergone non-operative treatment of at least six weeks (Fortilink-C) or at least six months (Fortilink-TS and Fortilink-L) prior to treatment with the IBF system. * The subject is willing and able to provide informed consent. * The subject is willing and able to attend the protocol required follow-up visits and examinations.

Exclusion criteria

* The subject has an active infection * The subject has had prior fusion attempt(s) or is undergoing revision of a previously implanted system at the involved level(s). * The subject is a worker's compensation case, in active litigation related to the procedure or is a prisoner or ward of the state. * The subject meets one or more of the contraindications outlined in the IFU. * The subject is pregnant, nursing, or is planning to become pregnant in the next year. * The subject has documented evidence of current substance abuse. * The subject has other concurrent medical condition that, in the opinion of the investigator, does not make the subject a good candidate for the study.

Design outcomes

Primary

MeasureTime frame
Rate of cervical fusion evaluated by radiographic evidence12 months
Rate of lumbar fusion evaluated by radiographic evidence24 months

Secondary

MeasureTime frameDescription
Time to return to workup to 24 months
Incidence of serious device related adverse eventsup to 24 months
Incidence of serious procedure related adverse eventsup to 24 months
Change in pain from baseline evaluated by use of subject-reported 100mm Visual Analogue Scale (VAS)1 month, 3 months, 6 months, 12 months, and 24 monthsThe VAS pain scale ranges from 0 to 100 where 0 represents No Pain and 100 represents Unbearable Pain.
Change in quality of life determined by SF-12 questionnaire3 months, 6 months, 12 months, and 24 monthsSF-12 questionnaires scores are computed and range from 0 to 100 where a 0 score indicates the lowest level of health and 100 indicates the highest level of health.
Change in pain medication usage from baseline1 month, 3 months, 6 months, 12 months, and 24 months
Change in functional ability determined by Neck Disability Index (NDI) or Oswestry Disability Index (ODI)3 months, 6 months, 12 months, and 24 monthsThe NDI is a subject questionnaire designed to assess neck pain and will only be completed by subjects who undergo cervical implants. The ODI is a subject questionnaire designed to assess back pain and will only be completed by subjects who undergo lumbar implants. Each questionnaire consists of a total score ranging from 0 to 100 where a lower score represents a better outcome and a higher score represents a worse outcome.
Radiographic findings by CT evaluation12 months and 24 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026